<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662019000500721</article-id>
<article-id pub-id-type="doi">10.24245/mim.v35i5.2658</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos secundarios metabólicos de los antipsicóticos de segunda generación]]></article-title>
<article-title xml:lang="en"><![CDATA[Metabolic side effects of second-generation antipsychotics]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Rojas]]></surname>
<given-names><![CDATA[Lupitha Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Zúñiga Hernández]]></surname>
<given-names><![CDATA[Leticia Arely]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Popular Autónoma del Estado de Puebla Facultad de Nutrición ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Popular Autónoma del Estado de Puebla  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>5</numero>
<fpage>721</fpage>
<lpage>731</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662019000500721&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662019000500721&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662019000500721&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Los antipsicóticos se prescriben ampliamente para el tratamiento de un gran número de problemas neuropsiquiátricos. Los antipsicóticos se dividen en dos clases de acuerdo con su estructura química, los típicos o de primera generación y los atípicos o de segunda generación. Estos últimos tienen mayores beneficios que los primeros porque producen menos efectos secundarios extrapiramidales; sin embargo, diversos estudios efectuados en humanos y en animales han relacionado su administración con efectos secundarios metabólicos, como obesidad, aumento de peso, diabetes, dislipidemias, síndrome metabólico y resistencia a la insulina. Debido a estos efectos se han establecido guías clínicas para el control y la vigilancia de los pacientes con algún tratamiento con este tipo de fármacos. El objetivo de este artículo es revisar algunos efectos secundarios metabólicos producidos por los antipsicóticos de segunda generación, así como su posible mecanismo de acción y el seguimiento o control metabólico que los pacientes en tratamiento con estos fármacos deben llevar. La búsqueda de los artículos se realizaron en las bases de datos PubMed, EBSCOHOST, DynaMed e IntraMed.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Antipsychotics are widely prescribed to treat a large number of neuropsychiatric problems. Antipsychotics are divided in two classes according to their chemical structure, typical or first generation and the atypical or second generation. The second-generation antipsychotics have greater benefits because they produce less extrapyramidal side effects; however, several studies in both humans and animals have related their administration to metabolic side effects, such as obesity, weight gain, diabetes, dyslipidemia, metabolic syndrome and insulin resistance. Because of the effects, clinical guidelines for the control and monitoring of patients with a treatment with these drugs have been established. The aim of this paper is to review some metabolic side effects produced by the second-generation antipsychotics and its possible mechanism of action, as well as the metabolic control or monitoring that patients treated with these drugs should have. The research of the articles was made in the databases: PubMed, EBSCOHOST, DynaMed and IntraMed.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antipsicótico atípico]]></kwd>
<kwd lng="es"><![CDATA[síndrome metabólico]]></kwd>
<kwd lng="es"><![CDATA[obesidad]]></kwd>
<kwd lng="es"><![CDATA[resistencia a la insulina]]></kwd>
<kwd lng="es"><![CDATA[diabetes]]></kwd>
<kwd lng="es"><![CDATA[hiperlipidemias]]></kwd>
<kwd lng="en"><![CDATA[Atypical antipsychotic]]></kwd>
<kwd lng="en"><![CDATA[Metabolic syndrome]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Insulin resistance]]></kwd>
<kwd lng="en"><![CDATA[Diabetes]]></kwd>
<kwd lng="en"><![CDATA[Hyperlipidemia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dale]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ritta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mcare]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacología]]></source>
<year>2004</year>
<edition>5</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aristil Chér]]></surname>
<given-names><![CDATA[P. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de Farmacología Básica y Clínica]]></source>
<year>2010</year>
<edition>5</edition>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Mc Graw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salín Pascual]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurobioquímica y farmacología de los antipsicóticos atípicos]]></article-title>
<source><![CDATA[Rev Mex Neuroci]]></source>
<year>2005</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>500-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flórez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fármacos antipsicóticos neurolépticos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Armijo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacología Humana]]></source>
<year>2008</year>
<edition>5</edition>
<page-range>629-44</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Company Plomer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[El uso de antipsicóticos de segunda generación en pacientes con esquizofrenia en edad adulta. ¿Modifica la morbimortalidad por enfermedad cardiovascular en comparación con los antipsicóticos de primera generación?]]></source>
<year>2016</year>
<page-range>4-7</page-range><publisher-name><![CDATA[Universitat de les Iles Balears]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Leon]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Crossley]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsicóticos de primera y segunda generación en esquizofrenia: eficacia, efectividad y efecto de la dosis utilizada]]></article-title>
<source><![CDATA[Rev Ciencias Médicas]]></source>
<year>2017</year>
<volume>42</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<collab>American Psychiatric Association</collab>
<collab>American Association of Clinical Endocrinologists</collab>
<collab>North American Association for the Study Of Obesity</collab>
<article-title xml:lang=""><![CDATA[Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2004</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>596-601</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llorente]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Urrutia]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes, Psychiatric disorders, and the metabolic effects of antipsychotic medications]]></article-title>
<source><![CDATA[Clinical Diabetes]]></source>
<year>2006</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marazziti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Piccini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dell'Osso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tendencias actuales en el tratamiento con antipsicóticos]]></article-title>
<source><![CDATA[Intramed]]></source>
<year>2017</year>
<volume>23</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2204-16</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jurgën Möller]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los efectos antipsicóticos y antidepresivos de los antipsicóticos de segunda generación. ¿Dos mecanismos farmacológicos diferentes?]]></article-title>
<source><![CDATA[RET Revista de Toxicomanías]]></source>
<year>2005</year>
<volume>44</volume>
<page-range>3-14</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alp]]></surname>
<given-names><![CDATA[Ü]]></given-names>
</name>
<name>
<surname><![CDATA[Wolfgang]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Side effects of atypical antipsychotics: a brief overview]]></article-title>
<source><![CDATA[World Psychiatry]]></source>
<year>2008</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-62</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Citromea]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vreeland]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and mental illness]]></article-title>
<source><![CDATA[Mod Trends Pharmacopsychiatry]]></source>
<year>2009</year>
<volume>26</volume>
<page-range>25-46</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortes Morales]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome metabólico y antipsicóticos de segunda generación]]></article-title>
<source><![CDATA[Rev Asoc Esp Neuropsiq]]></source>
<year>2011</year>
<volume>31</volume>
<numero>110</numero>
<issue>110</issue>
<page-range>303-20</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ascher-Svanum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chiang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Winstead]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration]]></article-title>
<source><![CDATA[BMC Psychiatry]]></source>
<year>2009</year>
<volume>9</volume>
<numero>80</numero>
<issue>80</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Newcomer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Valuck]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of baseline serum glucose and lipid testing in users of secod-generatios antipsychotic drugs: a retrospective, population-based study of Medicaid claims data]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>2008</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>316-22</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Brakoulias]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An evaluation of monitoring practices in patients on second generation antip-sychotics]]></article-title>
<source><![CDATA[Australas Psychiatry]]></source>
<year>2009</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>295-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1]]></article-title>
<source><![CDATA[Schizophr Res]]></source>
<year>2008</year>
<volume>103</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>104-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schooler]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Marder]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Chengappa]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Petrides]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ames]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wirshing]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clozapine and risperidone in moderalitely refractory schizophrenia: a 6 month randomized dpuble-blind comparison]]></article-title>
<source><![CDATA[J Clin Psych]]></source>
<year>2016</year>
<volume>77</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>628-34</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oviedo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bohórquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación y seguimiento metabólico del paciente con diagnóstico de esquizofrenia]]></article-title>
<source><![CDATA[Rev Colombiana de Psiquiatría]]></source>
<year>2015</year>
<volume>44</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>220-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnett]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[VonMuenster]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wehring]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Popish]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of monitoring for glucose and lipid dysregulation in adult Medical patients newly started on antipsychotics]]></article-title>
<source><![CDATA[Ann Clin Psychiat]]></source>
<year>2010</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-18</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coccurello]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Caprioli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ghirardi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Borsini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Carminati]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moles]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Olanzapine (LY170053, 2-methyl-4- (4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodia-zepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weigh gain, hyperphagia, and metabolic dysregulation in mice]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2008</year>
<volume>326</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>905-11</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Essock]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Covell]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[CT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotic drugs and schizophrenia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>354</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>298-300</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seeman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Secondary effects of antipsychotics: women at greater risk than men]]></article-title>
<source><![CDATA[Schizophrenia Bulletin]]></source>
<year>2009</year>
<volume>35</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>937-48</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dwyer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[X-H]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>2003</year>
<volume>971</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Obici]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2010</year>
<volume>59</volume>
<page-range>2418-25</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Houseknecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zavadoski]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2007</year>
<volume>32</volume>
<page-range>289-97</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolic syndrome and schizophrenia]]></article-title>
<source><![CDATA[Acta Psychiatr Scand]]></source>
<year>2009</year>
<volume>119</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-14</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants of atypical antipsychotic user in community-dwelling,1996-2004]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2008</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>709-16</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newcomer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome and mental illness]]></article-title>
<source><![CDATA[Am J Manag Care]]></source>
<year>2007</year>
<volume>13</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>S170-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Newcomer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kamat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baser]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Harnett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mcuffel]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2009</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1037-42</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mignon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Which comes first: atypical antipsychotic treatment or cardiometabolic risk?]]></article-title>
<source><![CDATA[Acta Psychiatr Scand]]></source>
<year>2009</year>
<volume>119</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>171-9</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Olanzapina induces SREBP | related adipogenesis in 3T3-Li cells]]></article-title>
<source><![CDATA[Pharmacol Res]]></source>
<year>2007</year>
<volume>56</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>202-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ader]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Catalano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ionut]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hucking]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Richey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kabir]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. A placebo controlled study of olanzapine and risperidone in dogs]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2005</year>
<volume>54</volume>
<page-range>862-71</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Obici]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[PJF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of brain in glucose metabolism]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Poretsky]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Principles of Diabetes Mellitus]]></source>
<year>2010</year>
<page-range>89-104</page-range><publisher-loc><![CDATA[Nueva York ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Konner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Janoschek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Plum]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jordan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rother]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Enriori]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hampel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Barsh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cowley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ashcroft]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bruning]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production]]></article-title>
<source><![CDATA[Cell Metab]]></source>
<year>2007</year>
<volume>5</volume>
<page-range>438-49</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Druss]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valuck]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Campagna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Newcomer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs]]></article-title>
<source><![CDATA[Arch Gen Psychiatry]]></source>
<year>2010</year>
<volume>67</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-24</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
